“I recognize this is biotech, not Tech, and it’s highly regulated and this is a new product.”
-All the more reason to bring in a big pharma partner with credibility, experience, and significant non dilutive cash right away. This management will take years to build any meaningful revenue and in the process dilute hundreds of millions of shares.
News 
Market Data 
Discover 
